Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies

The Lancet Psychiatry

Volumn 3, Issue 11, 2016, Pages 1059-1066

  Furukawa, Toshi A ^a   Cipriani, Andrea ^b   Atkinson, Lauren Z ^b   Leucht, Stefan ^c   Ogawa, Yusuke ^a   Takeshima, Nozomi ^a   Hayasaka, Yu ^a   Chaimani, Anna ^d,e   Salanti, Georgia ^d,e  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ARTICLE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84992183988     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(16)30307-8     Document Type: Article

References (31)

1. 1 Walsh, BT, Seidman, SN, Sysko, R, Gould, M, Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002), 1840–1847.
2. 2 Bridge, JA, Birmaher, B, Iyengar, S, Barbe, RP, Brent, DA, Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166 (2009), 42–49.
3. 3 Khan, A, Bhat, A, Kolts, R, Thase, ME, Brown, W, Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?. CNS Neurosci Ther 16 (2010), 217–226.
4. 4 Khin, NA, Chen, YF, Yang, Y, Yang, P, Laughren, TP, Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 72 (2011), 464–472.
5. 5 Fountoulakis, KN, Moller, HJ, Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14 (2011), 405–412.
6. 6 Rief, W, Nestoriuc, Y, Weiss, S, Welzel, E, Barsky, AJ, Hofmann, SG, Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 118 (2009), 1–8.
7. 7 Montgomery, SA, The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 9 (1999), 271–276.
8. 8 Rutherford, BR, Roose, SP, A model of placebo response in antidepressant clinical trials. Am J Psychiatry 170 (2013), 723–733.
9. 9 Sinyor, M, Levitt, AJ, Cheung, AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71 (2010), 270–279.
10. 10 Papakostas, GI, Fava, M, Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19 (2009), 34–40.
11. 11 Khan, A, Khan, SR, Walens, G, Kolts, R, Giller, EL, Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28 (2003), 552–557.
12. 12 Rutherford, BR, Cooper, TM, Persaud, A, Brown, PJ, Sneed, JR, Roose, SP, Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout. J Clin Psychiatry 74 (2013), 703–715.
13. 13 Landin, R, DeBrota, DJ, DeVries, TA, Potter, WZ, Demitrack, MA, The impact of restrictive entry criterion during the placebo lead-in period. Biometrics 56 (2000), 271–278.
14. 14 Undurraga, J, Baldessarini, RJ, Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37 (2012), 851–864.
15. 15 Furukawa, TA, Salanti, G, Atkinson, L, et al. Comparative efficacy and acceptability of first- and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open, 6, 2016, e010919.
16. 16 Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. http://www.cochrane-handbook.org (accessed June 28, 2016).
17. 17 DerSimonian, R, Laird, N, Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
18. 18 Furukawa, TA, Cipriani, A, Barbui, C, Brambilla, P, Watanabe, N, Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 20 (2005), 49–52.
19. 19 Spineli, LM, Higgins, JP, Cipriani, A, Leucht, S, Salanti, G, Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. Clin Trials 10 (2013), 378–388.
20. 20 Carmody, TJ, Rush, AJ, Bernstein, I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 16 (2006), 601–611.
21. 21 Stein, DJ, Baldwin, DS, Dolberg, OT, Despiegel, N, Bandelow, B, Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 67 (2006), 1741–1746.
22. 22 Agid, O, Siu, CO, Potkin, SG, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry 170 (2013), 1335–1344.
23. 23 Nikolakopoulou, A1, Mavridis, D, Salanti, G, Demystifying fixed and random effects meta-analysis. Evid Based Ment Health 17 (2014), 53–57.
24. 24 Drazen, JM, Sharing individual patient data from clinical trials. N Engl J Med 372 (2015), 201–202.
25. 25 Mancini, M, Wade, AG, Perugi, G, Lenox-Smith, A, Schacht, A, Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. J Psychiatr Res 51 (2014), 21–29.
26. 26 Weimer, K, Colloca, L, Enck, P, Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2 (2015), 246–257.
27. 27 Fava, M, Implications of a biosignature study of the placebo response in major depressive disorder. JAMA Psychiatry 72 (2015), 1073–1074.
28. 28 Cipriani, A, Geddes, JR, Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. BMC Med, 12, 2014, 105.
29. 29 Geddes, JR, Cipriani, A, Time to abandon placebo control in pivotal phase III trials?. World Psychiatry 14 (2015), 306–307.
30. 30 Rutherford, BR, Roose, SP, A model of placebo response in antidepressant clinical trials. Am J Psychiatry 170 (2013), 723–733.
31. 31 Norman, TC, Bountra, C, Edwards, AM, Yamamoto, KR, Friend, SH, Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci Transl Med, 3, 2011, 88mr1.